Home > Healthcare > Pharmaceuticals > Finished Drug Form > Tumor Necrosis Factor Inhibitor Drugs Market

Tumor Necrosis Factor Inhibitor Drugs Market Share

Report ID: GMI10748
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Tumor Necrosis Factor Inhibitor Drugs Market Share

The competitive landscape in the tumor necrosis factor (TNF) inhibitor drugs market is dynamic and highly competitive, driven by both established pharmaceutical giants and innovative biotechnology firms. Major players, such as AbbVie and Pfizer, dominate the market due to their strong brand presence and extensive clinical data supporting the efficacy and safety of their products. Newer entrants, including companies developing biosimilars and next-generation TNF inhibitors, are intensifying competition by offering cost-effective alternatives and potentially enhanced therapeutic profiles. Additionally, ongoing research and development efforts are focusing on improving the specificity and reducing the side effects of TNF inhibitors, further reshaping the market.

Tumor Necrosis Factor Inhibitor Drugs Market Companies

Prominent players operating in the tumor necrosis factor inhibitor drugs industry include:

AbbVie Inc.
Amgen Inc.
Boehringer Ingelheim Pharmaceuticals, Inc.
Bio-Thera Solutions, Ltd.
Janssen Biotech, Inc.
Merck & Co., Inc.
Pfizer Inc.
Samsung Bioepis Co., Ltd.
Sandoz Group AG
UCB, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The tumor necrosis factor inhibitor drugs market was valued at USD 41.3 billion in 2023 and is set to register 2.2% CAGR during 2024-2032 driven by the increasing prevalence of autoimmune diseases.

The rheumatoid arthritis segment in the market held 42% share in 2023 owing to the strong clinical efficacy and favorable safety profiles of these biologic drugs.

North America tumor necrosis factor inhibitor drugs market generated USD 17 billion in 2023 and is anticipated to reach USD 20 billion by 2032 attributed to the presence of leading pharmaceutical companies and biopharmaceutical firms.

AbbVie Inc., Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bio-Thera Solutions, Ltd., Janssen Biotech, Inc., Merck & Co., Inc., Pfizer Inc., Samsung Bioepis Co., Ltd., Sandoz Group AG, and UCB, Inc.